Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.
Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.
Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares describes how IL-4 is the key cytokine involved in the initiation and perpetuation of Th2 cell responses and type 2 inflammation.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 inflammation and barrier dysfunction contribute to the development of atopic comorbidities and increased susceptibility to infections.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.

Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the multidimensional and cumulative disease burden of AD and its associated comorbidities in children. Dr Boguniewicz also highlights the burden experienced by caregivers of children with AD

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.